pylori with clarithromycin-containing triple therapy reduced Actinobacteria diversity and increased the ermB resistance gene 1000-fold
A significant mechanistic advance is the reclassification of the classic inhibitor P4S
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
A recent study also demonstrated mislocalization of APE1 from the nucleus to the cytoplasm as a possible trigger of oxidative DNA damage in spinal motor neurons expressing mutant SOD1 G93A , despite upregulation of multiple DNA repair enzymes, suggesting that restricted localization of APE1 could inhibit redox homeostasis (Li J
In numerous epimutants (UR2, UR8 to UR30), a heterochromatin island impinges on the promoter region of the essential cup1 + gene (Torres-Garcia et al, 2020b), which encodes a mitochondrial LYR protein predicted to be an assembly factor for mitochondrial electron transport chain (ETC) complexes (Angerer, 2015)
All experiments were performed using cell lines from the fifth to tenth passage
